Next Article in Journal
In Vivo Effects of Quercetin in Association with Moderate Exercise Training in Improving Streptozotocin-Induced Aortic Tissue Injuries
Next Article in Special Issue
Understanding Critical Quality Attributes for Nanocrystals from Preparation to Delivery
Previous Article in Journal
Polyphenols from Bee Pollen: Structure, Absorption, Metabolism and Biological Activity
Previous Article in Special Issue
Determination of Solubility Parameters of Ibuprofen and Ibuprofen Lysinate
Article Menu

Export Article

Open AccessReview
Molecules 2015, 20(12), 21750-21769; doi:10.3390/molecules201219804

Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy

Department of Biochemistry, University of Mississippi Medical Center, 2500 North State Street Jackson, MS 39216, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Thomas Rades, Holger Grohganz and Korbinian Löbmann
Received: 25 September 2015 / Revised: 5 November 2015 / Accepted: 17 November 2015 / Published: 4 December 2015
(This article belongs to the Collection Poorly Soluble Drugs)
View Full-Text   |   Download PDF [1505 KB, uploaded 4 December 2015]   |  

Abstract

The majority of anticancer drugs have poor aqueous solubility, produce adverse effects in healthy tissue, and thus impose major limitations on both clinical efficacy and therapeutic safety of cancer chemotherapy. To help circumvent problems associated with solubility, most cancer drugs are now formulated with co-solubilizers. However, these agents often also introduce severe side effects, thereby restricting effective treatment and patient quality of life. A promising approach to addressing problems in anticancer drug solubility and selectivity is their conjugation with polymeric carriers to form polymer-based prodrugs. These polymer-based prodrugs are macromolecular carriers, designed to increase the aqueous solubility of antitumor drugs, can enhance bioavailability. Additionally, polymer-based prodrugs approach exploits unique features of tumor physiology to passively facilitate intratumoral accumulation, and so improve chemodrug pharmacokinetics and pharmacological properties. This review introduces basic concepts of polymer-based prodrugs, provides an overview of currently emerging synthetic, natural, and genetically engineered polymers that now deliver anticancer drugs in preclinical or clinical trials, and highlights their major anticipated applications in anticancer therapies. View Full-Text
Keywords: polymer based prodrugs; anticancer drugs; macromolecules; drug delivery; cancer therapy; genetically engineered biopolymers; synthetic and natural polymers polymer based prodrugs; anticancer drugs; macromolecules; drug delivery; cancer therapy; genetically engineered biopolymers; synthetic and natural polymers
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Dragojevic, S.; Ryu, J.S.; Raucher, D. Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy. Molecules 2015, 20, 21750-21769.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top